{"filing":{"accession_number":"0001493152-26-041894","cik":"0001712762","ticker":"BIAFW","company_name":"bioAffinity Technologies, Inc.","form":"8-K","filing_date":"2026-09-09","report_date":"2026-09-08","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315226041894/form8-k.htm"},"events":[{"id":32232,"run_id":29613,"accession_number":"0001493152-26-041894","anchor_item_number":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"The filing discloses that bioAffinity Technologies received notice from Nasdaq on July 30, 2026, that it had failed to maintain the minimum bid price of $1.00 per share required under Nasdaq Listing Rule 5550(a)(2), and was therefore not in compliance with continued listing requirements. Although the company subsequently regained compliance by September 8, 2026 (as confirmed in the Written Notice), the core event disclosed is the delisting risk and the company's appeal process to avoid delisting. This is material to investors as it directly affects the company's ability to remain listed on Nasdaq.","company_name":"bioAffinity Technologies, Inc.","ticker":"BIAFW","filing_date":"2026-09-09","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":35354,"accession_number":"0001493152-26-041894","item_number":null,"item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that bioAffinity Technologies received notice from Nasdaq on July 30, 2026, that it had failed to maintain the minimum bid price of $1.00 per share required under Nasdaq Listing Rule 5550(a)(2), and was therefore not in compliance with continued listing requirements. Although the company subsequently regained compliance by September 8, 2026 (as confirmed in the Written Notice), the core event disclosed is the delisting risk and the company's appeal process to avoid delisting. This is material to investors as it directly affects the company's ability to remain listed on Nasdaq.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T12:31:42.782858+00:00","company_name":"bioAffinity Technologies, Inc.","ticker":"BIAFW","filing_date":"2026-09-09"}]}